Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT07780552

CHIP in Health and Disease

Sponsor: VASCage GmbH

View on ClinicalTrials.gov

Summary

Clonal hematopoiesis (CH), including clonal hematopoiesis of indeterminate potential (CHIP), is an age-associated condition characterized by the expansion of hematopoietic stem and progenitor cell clones carrying acquired somatic mutations. Although CH is associated with an increased risk of hematologic malignancies, its greater public health impact derives from its strong association with cardiovascular diseases, including coronary artery disease and stroke. Emerging evidence suggests that CH-associated mutations promote chronic inflammatory signaling in myeloid immune cells, thereby contributing to atherosclerosis and adverse cardiovascular remodeling. This observational translational study aims to characterize the biological spectrum of clonal hematopoiesis across different stages of disease risk and manifestation. Using state-of-the-art single-cell and multi-omics approaches, the study will compare inflammatory pathways, immune cell states, and mutation-associated molecular programs among healthy individuals without CH, individuals with high-risk CH, and patients with CH-associated hematologic or cardiovascular disease. The ultimate goal is to identify shared and disease-specific mechanisms linking clonal hematopoiesis to adverse clinical outcomes and to generate insights for future preventive, anti-clonal, and anti-inflammatory therapeutic strategies.

Official title: DECONVOLUTION OF CLONAL HEMATOPOIESIS ASSOCIATED INFLAMMATION IN HEALTH AND DISEASE

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

120

Start Date

2026-10

Completion Date

2027-03

Last Updated

2026-08-21

Healthy Volunteers

Yes

Conditions

Clonal Hematopoiesis Clonal Hematopoiesis of Indeterminate Potential Clonal Cytopenia of Undetermined Significance (CCUS)Myelodysplastic Syndrome Cardiovascular Disease Myocardial Infarction (MI)ST-elevation Myocardial Infarction (STEMI)

Inclusion Criteria: Participants must be ≥18 years of age and meet at least one of the following criteria: * Written informed consent has been obtained for participation in the study "Deconvolution of Clonal Hematopoiesis-Associated Inflammation in Health and Disease"; OR * Participant is enrolled in the Inn.Health study and has provided written informed consent; OR * Participant is enrolled in the study "Clonal Hematopoiesis of Indeterminate Potential and Infarct Severity in ST-Elevation Myocardial Infarction" and has provided written informed consent. Group A: Control Group (n=20) * Age ≥60 years * No detectable somatic variant identified by peripheral blood next-generation sequencing (NGS) * No history of stroke or myocardial infarction * No surgery within the previous 3 months * No diagnosis of a WHO-defined neoplasm * No cytopenia at study enrollment Group B: Low-Risk Clonal Hematopoiesis Risk Score (CHRS) Group (n=20) * Age ≥60 years * Somatic variant in DNMT3A, TET2, ASXL1, or JAK2 with variant allele frequency (VAF) ≥2% in peripheral blood * No history of stroke or myocardial infarction * No surgery within the previous 3 months * No diagnosis of a WHO-defined neoplasm * No cytopenia at study enrollment * Low-risk CHRS (\<9.5 points) Group C: Intermediate-/High-Risk CHRS Group (n=20) * Age ≥60 years * Somatic variant in DNMT3A, TET2, ASXL1, or JAK2 with VAF ≥2% in peripheral blood * No history of stroke or myocardial infarction * No surgery within the previous 3 months * No diagnosis of a WHO-defined neoplasm * No cytopenia at study enrollment * Intermediate- or high-risk CHRS (\>9.5 points) Group D: Clonal Cytopenia of Undetermined Significance (CCUS) Group (n=20) * Age ≥60 years * Somatic variant in DNMT3A, TET2, ASXL1, or JAK2 with VAF ≥2% in peripheral blood * No history of stroke or myocardial infarction * No surgery within the previous 3 months * No diagnosis of a WHO-defined neoplasm * Untreated, unexplained cytopenia present for ≥4 months * Hemoglobin \<13 g/dL (men) or \<12 g/dL (women), and/or absolute neutrophil count \<1.8 × 10⁹/L, and/or platelet count \<150 × 10⁹/L * No diagnostic criteria for a defined myeloid neoplasm based on bone marrow examination Group E: Cardiovascular Disease Group (n=20) * Age ≥60 years * Somatic variant in DNMT3A, TET2, ASXL1, or JAK2 with VAF ≥2% in peripheral blood * ST-segment elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention (PCI) within the previous 4 months * No history of coronary artery bypass grafting (CABG) * No history of stroke * No cytopenia at study enrollment * No diagnosis of a WHO-defined neoplasm Group F: Low-Risk Myelodysplastic Syndrome (MDS) Group (n=20) * Age ≥60 years * Untreated, newly diagnosed (\<3 months from diagnosis) low-risk myelodysplastic syndrome according to the Revised International Prognostic Scoring System (IPSS-R score \>1.5 to 3.0) * No history of stroke or myocardial infarction Exclusion Criteria: * Treatment with immunosuppressive medication within the previous 4 weeks, including but not limited to systemic corticosteroids, methotrexate, other disease-modifying antirheumatic drugs (DMARDs), colchicine, TNF-α inhibitors, mTOR inhibitors, calcineurin inhibitors, or immunomodulatory antibodies * History of rheumatologic, autoinflammatory, or autoimmune disease

Locations (1)

Medical University Innsbruck

Innsbruck, Tyrol, Austria